Normalization of total testosterone levels after TRT was associated with a significant reduction in all-cause mortality, MI, and stroke
Objective: To examine the relationship between the normalization of total testosterone (TT) after TRT and CV events as well as all-cause mortality in patients without previous history of MI and stroke
83,010 male veterans with documented low TT levels
Conclusions: Normalization of TT levels after TRT was associated with a significant reduction in all-cause mortality, MI, and stroke.
To read the case study please click HERE
Sharma, R., Oni, O. A., Gupta, K., Chen, G., Sharma, M., Dawn, B., Sharma, R., Parashara, D., Savin, V. J., Ambrose, J. A., & Barua, R. S. (2015). Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. European heart journal, 36(40), 2706–2715. https://doi.org/10.1093/eurheartj/ehv346
--
Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
Objective: The association between erectile dysfunction (ED), hypogonadism, cardiovascular disease, and type 2 diabetes is well documented, but long-term data are limited. The aim of this study is to investigate effects of long-term testosterone therapy (TTh) with testosterone undecanoate in men with hypogonadism and ED.
805 hypogonadal men with different degrees of ED
412 patients w/ testosterone therapy
393 patients served as controls
Observation period up to 12 years
Patients must stay on testosterone therapy consistently for a long time to achieve maximum benefits
Conclusions: Long-term testosterone therapy alleviates ED, improves cardiometabolic risk factors, and reduces prostate cancer
To read the case study please click HERE
Saad, F., Caliber, M., Doros, G., Haider, K. S., & Haider, A. (2020). Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. The aging male : the official journal of the International Society for the Study of the Aging Male, 23(1), 81–92. https://doi.org/10.1080/13685538.2019.157535
--
Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study
Objective: To investigate whether testosterone therapy in men with hypogonadism and type 2 diabetes mellitus improves glycemic control and insulin sensitivity, and results in remission of T2DM.
365 men with symptoms of TD
Followed over 11 years
All were treated with standard diabetes treatment
178 received parenteral testosterone undecanoate 1000mg every 12 weeks
Control group not treated with T
Results:
Patients treated with T had significant progressive and sustained reductions in fasting glucose, glycated hemoglobin (HbA1c), and fasting insulin
Control group fasting glucose, HbA1c, and fasting insulin increased.
Patients treated with T
34.3% achieved remission of their diabetes
46.6% of patients achieved normal glucose regulation
83.1% reached the HbA1c target of 47.5 mmol/mol (6.5%) and
90% achieved the HbA1c target of 53.0 mmol/mol (7%).
Control group
No remission
No noted reductions in glucose of HbA1c
Conclusions: Long‐term TTh in men with T2DM and hypogonadism improves glycaemic control and insulin resistance. Remission of diabetes occurred in one‐third of the patients. TTh is potentially a novel additional therapy for men with T2DM and hypogonadism.
To read the case study please click HERE
Haider KS, Haider A, Saad F, Doros G, Hanefeld M, Dhindsa S, Dandona P, Traish A. Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study. Diabetes Obes Metab. 2020 Nov;22(11):2055-2068. doi: 10.1111/dom.14122. Epub 2020 Jul 15. PMID: 32558149; PMCID: PMC7689919.